Yahoo
    NasdaqCM - Delayed Quote USD

    Estrella Immunopharma, Inc. (ESLA)

    0.6393 -0.0894 (-12.27%)
    At close: October 30 at 4:00:01 PM EDT
    Loading Chart for ESLA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

    Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
    Business Wire 6d ago
    Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

    Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
    Business Wire 16d ago
    Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

    Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
    Business Wire 17d ago
    ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

    ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
    Zacks Small Cap Research 2mo ago
    Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

    Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
    Business Wire 2mo ago
    Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

    Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
    Business Wire 3mo ago
    Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

    Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
    Business Wire 3mo ago
    ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

    ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL
    Zacks Small Cap Research 8mo ago
    ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?

    ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?
    Zacks Small Cap Research 3mo ago
    Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

    Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
    Business Wire 2mo ago
    ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T

    ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T
    Zacks Small Cap Research 7mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: